Upcoming Ex-Dividend Dates for Cognex, SBA Communications, and Ingersoll Rand
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2025
0mins
Should l Buy IR?
Source: NASDAQ.COM
Upcoming Ex-Dividend Dates: Cognex Corp (CGNX), SBA Communications Corp (SBAC), and Ingersoll Rand Inc (IR) will trade ex-dividend on 11/13/25, with respective dividends of $0.085, $1.11, and $0.02 scheduled for payment on 11/28/25, 12/11/25, and 12/4/25.
Expected Price Adjustments: Following the ex-dividend date, CGNX shares are expected to drop by approximately 0.22%, SBAC by 0.56%, and IR by 0.03%, based on their recent stock prices.
Dividend Yield Estimates: The estimated annualized yields for the upcoming dividends are 0.88% for Cognex Corp, 2.23% for SBA Communications Corp, and 0.10% for Ingersoll Rand Inc, reflecting their historical dividend stability.
Current Stock Performance: As of the latest trading session, Cognex Corp shares are down about 1.8%, SBA Communications Corp shares are up about 1%, and Ingersoll Rand Inc shares are down about 0.4%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IR
Wall Street analysts forecast IR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IR is 90.50 USD with a low forecast of 81.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 96.000
Low
81.00
Averages
90.50
High
100.00
Current: 96.000
Low
81.00
Averages
90.50
High
100.00
About IR
Ingersoll Rand Inc. is a provider of mission-critical flow creation and life sciences and industrial solutions. Its Industrial Technologies and Services segment designs, manufactures, markets and services a range of compression and vacuum equipment as well as fluid transfer equipment, and loading systems. Its compression and vacuum products are used worldwide in industrial manufacturing, transportation, chemical processing, food and beverage production, clean energy, environmental and other applications. The Precision and Science Technologies segment, designs, manufactures and markets a broad range of specialized positive displacement pumps, fluid management equipment, single-use powder handling systems, and contract design and production services for silicone, thermoplastic, and specialty components and assemblies for medical devices. It also designs and manufactures plastic product solutions for life science and healthcare technology industries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Jobs and Inflation Data Set for Release
- Job Data Expectations: The U.S. is expected to add 60,000 jobs in January, up from 50,000 in December, which could influence the Fed's monetary policy direction amidst ongoing economic uncertainty.
- Inflation Metrics Analysis: The January Consumer Price Index is projected to rise by 0.29% month-over-month and 2.5% year-over-year, showing improvement but still falling short of the Fed's 2% target, potentially affecting investor rate expectations.
- Market Reaction and Risks: Recent signs of labor market weakness, including an ADP report indicating only 22,000 new private sector jobs, may heighten expectations for further Fed rate cuts, although investors remain optimistic about economic resilience.
- Stock Market Rotation Trend: A significant rotation within the stock market is underway, with the Dow Jones Industrial Average rising over 2% this week, reflecting confidence in economic recovery, despite ongoing weakness in tech stocks.
See More
Ingersoll Rand and Others Face Severe EPS Downgrades Ahead of Earnings Season
- Earnings Downgrades: Ingersoll Rand Inc. (IR) faces the steepest earnings downgrades with an EPS revision grade of F and a Quant rating of 2.04, indicating strong analyst concerns about its near-term performance, which may lead to decreased investor confidence.
- Industry Pressure: Kuehne + Nagel International AG (KHNGY) also suffers from an F EPS revision grade and a Quant rating of 2.67, suggesting doubts about its competitiveness in the global logistics sector, potentially affecting its future market share.
- Multiple Companies Challenged: Owens Corning (OC) and Komatsu Ltd. (KMTUY) are rated F with Quant ratings of 1.76 and 2.02 respectively, highlighting significant challenges in profitability and market performance, which could lead to stock price volatility.
- Analyst Skepticism: Overall, among 20 large-cap industrial companies, the majority have EPS revision grades of D- or F, reflecting a pessimistic outlook from analysts regarding their earnings capabilities, which may influence investor decisions and market sentiment.
See More
Ingersoll Rand (IR) Schedules Q4 2025 Earnings Release and Conference Call
- Earnings Release Schedule: Ingersoll Rand is set to release its Q4 2025 earnings after market close on February 12, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Timing: The company will host a conference call on February 13, 2026, at 8 a.m. Eastern Time to discuss the earnings results, aiming to enhance interaction and information sharing with investors.
- Participation Details: Investors can join the call by dialing +1-888-330-3073 domestically or +1-646-960-0683 internationally, using access code 8970061, ensuring broad dissemination of information.
- Webcast Replay Availability: A replay of the webcast will be accessible on Ingersoll Rand's Investor Relations website after the conference, further improving the accessibility and transparency of company information.
See More
Wells Fargo Sees Rebound Potential in Heavily Shorted Stocks, Herc Target Price Implies 27% Upside
- Market Rebound Expectations: Wells Fargo anticipates a market 'reflation' and short squeeze driven by tax refunds averaging $800 per person, which will propel stock prices higher, particularly for lagging stocks with significant short positions.
- Herc Holdings Outlook: Herc Holdings has declined 15% over the past year, yet KeyBanc upgraded its rating to overweight with a $200 price target, implying a 27% upside, reflecting confidence that initial integration challenges post-HEES deal are largely resolved.
- Cost Synergy Goals: Herc aims to achieve approximately $125 million in targeted cost synergies by the end of FY26, with analysts believing that a stabilized salesforce will allow the company to focus on this goal, thereby enhancing profitability.
- Vera Therapeutics Potential: Wells Fargo highlights Vera Therapeutics, projecting that its lead drug atacicept will excel in a multibillion-dollar market, expected to outperform consensus and alleviate concerns regarding competitive risks.
See More
Ingersoll Rand Acquires Scinomix to Expand Life Sciences Portfolio
- Strategic Acquisition: Ingersoll Rand's acquisition of Scinomix at an attractive pre-synergy purchase multiple of approximately 10x 2025 Adjusted EBITDA significantly enhances its competitive position in the life sciences sector.
- Technology Integration: This acquisition enables the combination of Scinomix's automation technologies with Ingersoll Rand's existing solutions, allowing the company to provide comprehensive end-to-end laboratory solutions that enhance workflow efficiency and accuracy for customers.
- Market Expansion: The addition of Scinomix not only enriches Ingersoll Rand's product portfolio but also opens new opportunities for market expansion across various industries, including clinical, pharmaceutical, and biotechnology, further solidifying its leadership in the life sciences field.
- Innovation-Driven: CEO Vicente Reynal stated that this acquisition will drive the expansion of innovative solutions, helping to better serve customers and increase market share, reflecting the company's long-term commitment to the life sciences sector.
See More
Quanterix Unveils Leadership and Board Changes to Facilitate Future Growth
Leadership Appointments: Quanterix Corporation has appointed Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to its Board of Directors, while William Donnelly has been named Executive Chair and Jeffrey Elliott as Lead Independent Director.
Strategic Focus: The leadership changes aim to support Quanterix's growth initiatives, including expanding its biomarker offerings and launching new diagnostic tools, particularly for Alzheimer's disease.
Board Composition Changes: Paul Meister and David Walt, Ph.D., are stepping down from the Board, leaving Quanterix with a total of nine board members, seven of whom are independent.
Future Outlook: The new board members bring extensive experience in life sciences and diagnostics, which is expected to enhance Quanterix's strategic direction and operational alignment as it integrates recent acquisitions and focuses on growth.
See More
U.S. Jobs and Inflation Data Set for Release
- Job Data Expectations: The U.S. is expected to add 60,000 jobs in January, up from 50,000 in December, which could influence the Fed's monetary policy direction amidst ongoing economic uncertainty.
- Inflation Metrics Analysis: The January Consumer Price Index is projected to rise by 0.29% month-over-month and 2.5% year-over-year, showing improvement but still falling short of the Fed's 2% target, potentially affecting investor rate expectations.
- Market Reaction and Risks: Recent signs of labor market weakness, including an ADP report indicating only 22,000 new private sector jobs, may heighten expectations for further Fed rate cuts, although investors remain optimistic about economic resilience.
- Stock Market Rotation Trend: A significant rotation within the stock market is underway, with the Dow Jones Industrial Average rising over 2% this week, reflecting confidence in economic recovery, despite ongoing weakness in tech stocks.
See More
Ingersoll Rand and Others Face Severe EPS Downgrades Ahead of Earnings Season
- Earnings Downgrades: Ingersoll Rand Inc. (IR) faces the steepest earnings downgrades with an EPS revision grade of F and a Quant rating of 2.04, indicating strong analyst concerns about its near-term performance, which may lead to decreased investor confidence.
- Industry Pressure: Kuehne + Nagel International AG (KHNGY) also suffers from an F EPS revision grade and a Quant rating of 2.67, suggesting doubts about its competitiveness in the global logistics sector, potentially affecting its future market share.
- Multiple Companies Challenged: Owens Corning (OC) and Komatsu Ltd. (KMTUY) are rated F with Quant ratings of 1.76 and 2.02 respectively, highlighting significant challenges in profitability and market performance, which could lead to stock price volatility.
- Analyst Skepticism: Overall, among 20 large-cap industrial companies, the majority have EPS revision grades of D- or F, reflecting a pessimistic outlook from analysts regarding their earnings capabilities, which may influence investor decisions and market sentiment.
See More
Ingersoll Rand (IR) Schedules Q4 2025 Earnings Release and Conference Call
- Earnings Release Schedule: Ingersoll Rand is set to release its Q4 2025 earnings after market close on February 12, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Timing: The company will host a conference call on February 13, 2026, at 8 a.m. Eastern Time to discuss the earnings results, aiming to enhance interaction and information sharing with investors.
- Participation Details: Investors can join the call by dialing +1-888-330-3073 domestically or +1-646-960-0683 internationally, using access code 8970061, ensuring broad dissemination of information.
- Webcast Replay Availability: A replay of the webcast will be accessible on Ingersoll Rand's Investor Relations website after the conference, further improving the accessibility and transparency of company information.
See More
Wells Fargo Sees Rebound Potential in Heavily Shorted Stocks, Herc Target Price Implies 27% Upside
- Market Rebound Expectations: Wells Fargo anticipates a market 'reflation' and short squeeze driven by tax refunds averaging $800 per person, which will propel stock prices higher, particularly for lagging stocks with significant short positions.
- Herc Holdings Outlook: Herc Holdings has declined 15% over the past year, yet KeyBanc upgraded its rating to overweight with a $200 price target, implying a 27% upside, reflecting confidence that initial integration challenges post-HEES deal are largely resolved.
- Cost Synergy Goals: Herc aims to achieve approximately $125 million in targeted cost synergies by the end of FY26, with analysts believing that a stabilized salesforce will allow the company to focus on this goal, thereby enhancing profitability.
- Vera Therapeutics Potential: Wells Fargo highlights Vera Therapeutics, projecting that its lead drug atacicept will excel in a multibillion-dollar market, expected to outperform consensus and alleviate concerns regarding competitive risks.
See More
Ingersoll Rand Acquires Scinomix to Expand Life Sciences Portfolio
- Strategic Acquisition: Ingersoll Rand's acquisition of Scinomix at an attractive pre-synergy purchase multiple of approximately 10x 2025 Adjusted EBITDA significantly enhances its competitive position in the life sciences sector.
- Technology Integration: This acquisition enables the combination of Scinomix's automation technologies with Ingersoll Rand's existing solutions, allowing the company to provide comprehensive end-to-end laboratory solutions that enhance workflow efficiency and accuracy for customers.
- Market Expansion: The addition of Scinomix not only enriches Ingersoll Rand's product portfolio but also opens new opportunities for market expansion across various industries, including clinical, pharmaceutical, and biotechnology, further solidifying its leadership in the life sciences field.
- Innovation-Driven: CEO Vicente Reynal stated that this acquisition will drive the expansion of innovative solutions, helping to better serve customers and increase market share, reflecting the company's long-term commitment to the life sciences sector.
See More
Quanterix Unveils Leadership and Board Changes to Facilitate Future Growth
Leadership Appointments: Quanterix Corporation has appointed Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to its Board of Directors, while William Donnelly has been named Executive Chair and Jeffrey Elliott as Lead Independent Director.
Strategic Focus: The leadership changes aim to support Quanterix's growth initiatives, including expanding its biomarker offerings and launching new diagnostic tools, particularly for Alzheimer's disease.
Board Composition Changes: Paul Meister and David Walt, Ph.D., are stepping down from the Board, leaving Quanterix with a total of nine board members, seven of whom are independent.
Future Outlook: The new board members bring extensive experience in life sciences and diagnostics, which is expected to enhance Quanterix's strategic direction and operational alignment as it integrates recent acquisitions and focuses on growth.
See More
